Clinical stage biopharmaceutical company Pulmatrix has announced a licensing agreement with Johnson & Johnson this week. The Massachusetts-based company entered a licensing and development agreement with the Lung Cancer Initiative at J&J, providing the latter an option to access a portfolio of narrow spectrum kinase inhibitors intended for development in lung cancer interception. Pulmatrix, which … Continue reading “Pulmatrix Inc. Scores Licensing Agreement with Johnson & Johnson”
